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patients (22% of those treated with one-daily dosing). Those
subjects showed lower values in several dimensions of the quality
of life. This is a new way to estimate the GPAO and HTO preva-
lence. This allowed to give a useful approximation to profes-
sionals involved in ocular diseases medical, economical and
societal management. CONCLUSION: On the basis of this ﬁrst
nationwide study, it can be estimated that the prevalence of 
subjects treated with IOP-lowering topical medications is about
1.2 million in France. Number of daily doses appear to inﬂuence
compliance.
EYE—Cost Studies
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OBJECTIVES: Epidemiological data support an association
between age-related macular degeneration (AMD) and cataract
surgery that may be attributed to post-operative blue light expo-
sure. By limiting the retina’s blue light exposure, new blue-light
ﬁltering intraocular lenses (BLF IOLs) have the potential to
reduce the development of AMD following cataract surgery. In
the current economic healthcare environment, there is increased
interest in the cost-effectiveness of new medical technologies.
The objective of this analysis was to evaluate the cost-effective-
ness of a BLF IOL versus a non-BLF IOL in cataract surgery.
METHODS: An economic model was developed to emulate
three age-speciﬁc cohorts and to assess the clinical and economic
outcomes over 5 years. Data from the published literature was
supplemented with clinical expert opinion. Key clinical inputs
were the risk of AMD after cataract surgery and the effective-
ness of the BLF IOL in reducing the risk of AMD. Direct medical
costs including the cost of the IOL, monitoring, and AMD pro-
phylaxis and treatment were incorporated into the model. All
costs were standardized to 2004 US dollars. Age-stratiﬁed base-
case and sensitivity analyses were conducted. RESULTS: In the
BLF IOL group, the 5-year age-stratiﬁed incidence of AMD
ranged from 0.58 to 9.23 per 100 eyes, compared with 1.69 to
24.55 per 100 eyes in the non-BLF IOL group. The incremental
cost of the BLF was offset by reduced costs associated with
averted AMD treatment. Estimated savings with BLF IOLs per
100 eyes were $4275, $29,997, and $111,734 in the 55 to 64
year-old, 65 to 74 year-old, and ≥75-year-old cohorts, respec-
tively; these ﬁndings remained robust across the sensitivity analy-
ses. CONCLUSION: This study suggests that the economic
beneﬁts of implanting BLF IOLs during cataract surgery are
observed in all patients although cost savings are greatest in
patients ≥75 years.
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OBJECTIVE: Exudative age-related macular degeneration
(AMD) is the most common cause of blindness among older
Americans in the United States. No substantive information on
costs for exudative AMD was found in the literature. This study
estimates incremental costs for the disease. METHODS: Seven
years (1994–2000) of 5% sample of Medicare medical claims
data from the Standard Analytical File (SAF) was used. We fol-
lowed AMD and control patients with an index date starting in
1996 for two years. Incremental cost was deﬁned as the excess
cost for exudative AMD cohort over that of an age-gender-
matched non-exudative-AMD group based on Medicare reim-
bursed expenditures. We also estimated the 10-year projected
cost using Medical Price Index. Cost from AMD related comor-
bid conditions, such as depression which could worsen as the
result of the progression in exudative AMD, were evaluated indi-
vidually. RESULTS: A total of 3059 wet AMD patients were
identiﬁed and a cohort of non-wet-AMD with same size was also
created. Two years’ incremental medical cost for wet AMD
patients compared to the controlled cohort is $2689, including
$485 (18%) for inpatient hospital, $1132 (42%) for outpatient
hospital, and $1034 (38%) for ofﬁce visits. The 10-year pro-
jected cost was $16,148, including $6795 for outpatient hospi-
tal and $6207 for ofﬁce visit. Incremental cost of depression
almost doubled 1 year after the diagnosis of wet AMD, increas-
ing from $64/year to $118/year. CONCLUSION: Excess cost for
wet AMD after initial diagnosis was substantial. This research
does not incorporate Medicaid covered expenses and out of
pocket costs. With the aging population and people living longer,
the economic burden of this disease will increase. This informa-
tion may help researchers and policy makers in assessing beneﬁt
and increase use of approved AMD therapies, such as Macugen
(pegaptanib sodium) to help determine the clinical and economic
beneﬁts to patients and society.
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OBJECTIVES: ARMD is the leading cause of blindness for
people aged 60 and over in the US, resulting in signiﬁcant visual
ﬁeld losses, and consequent occurrences of serious vision-related
conditions and events, reductions in health-related quality of life,
and economic costs. The research objective was to assess the
incremental cost-utility of Visudyne®, relative to usual care of
ARMD. METHODS: A Markov cohort model was developed to
simulate progressive loss of visual acuity, treatment alternatives
and consequent clinical events and costs. Efﬁcacy of Visudyne®
was based on pooled results of three two-year randomized
placebo-controlled trials, and extrapolated to a horizon of 15
years. Treatment was assumed to be discontinued after two
years. Extrapolation of clinical trial results for both the treat-
ment and usual care arms of the model were based on the usual
care outcomes. Patients were grouped based on lesion type and
size. Relative risks and costs of serious clinical events (e.g., hip
fractures, nursing home placement), and utilities associated with
levels of visual acuity were derived from the literature. Incre-
mental cost-effectiveness ratios (ICERs) were expressed as 2004
US dollars per quality-adjusted life year ($/QALY). One-way sen-
sitivity analyses were performed with respect to efﬁcacy, the pro-
portion of patients receiving treatment for the better-seeing eye,
and other clinical, utility, and cost parameters. RESULTS: The
ICER of Visudyne® was $35,200/QALY, and was most sensitive
to the proportion of patients whose treatment was in the better-
seeing eye, the source for utilities, and the distribution of patients
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among vision states at baseline. The incremental cost per vision
year saved, deﬁned as one additional year spent in any state
better than legal blindness, was estimated to be $13,100. CON-
CLUSIONS: Visudyne® is reasonably cost-effective compared to
usual care. The model is capable of analyzing the many new and
combination therapies anticipated in the near future.
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OBJECTIVE: To assess utilization patterns of cyclosporine oph-
thalmic emulsion 0.05% (cyclosporine) within managed care
using a claims database. METHODS: Patients with at least one
prescription for cyclosporine over a 3-month enrollment period
and at least one reﬁll prescription over the 12-month follow-up
period were included in the analysis. If the patient did not have
a prescription for cyclosporine during the 12 months prior to the
enrollment period, the patient was classiﬁed as a new patient
while patients with at least one prescription for cyclosporine
during the prior use period were considered a continuing patient.
Daily, monthly, and annual utilizations were assessed for the 
two cohorts. Based on this retrospective approach, no data on
efﬁcacy were available for analysis. RESULTS: A total of 38,164
patients met the inclusion criteria and a majority (59%) was new
to therapy, female (82%), and 50 years or older (77%). Per
Federal Drug Administration (FDA)-approved use, a patient is
recommended to use 2 vials per day (2 trays per month or 24
trays per year). On average, 73% of the patients used 1 tray per
month based on an analysis of prescription reﬁll patterns.
Annual data was similar in that 80% of the patients used 11
trays or less per year. Daily utilization differed between contin-
uing and new patients. New patients had a bimodal use pattern
as over 30% were using ≥1.75 vials per day and approximately
55% were using 0.25 to 1.25 vials per day. The majority of con-
tinuing patients, however, (approximately 80%) used 0.25 to
1.25 vials per day. CONCLUSIONS: While some new patients
take cyclosporine as prescribed (2 vials per day), the majority of
continuing patients follows a utilization pattern of approxi-
mately 1 vial per day. As such, the impact on a managed care
budget may be signiﬁcantly less than originally estimated.
EYE—Health Care Use & Policy Studies
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OBJECTIVES: Topical beta-blockers and prostaglandin analogs
are widely used for the treatment of primary open-angle glau-
coma. The objective of this study was to examine the trend in
prescribing patterns of topical glaucoma medications. In addi-
tion, we also examined the association between socioeconomic
factors related to patients as well as physicians with the pre-
scribing patterns of topical glaucoma medications. METHODS:
This retrospective cross sectional study utilized the National
Ambulatory Medical Care Survey data from 1999–2003.
Patients aged °Y´18 years who received treatment for glaucoma
in US outpatient settings over this period were included. Ofﬁce
visits were considered to be glaucoma related, if ICD-9 diagno-
sis codes for glaucoma were reported, if glaucoma was reported
as the reason of visit, and if any glaucoma medication was pre-
scribed. Weighted logistic regression was used to examine study
objectives. RESULTS: Prostaglandin analogs and beta-blockers
were prescribed in 8.8 million and 6.8 million outpatient visits
respectively during years 1999–2003 (total weighted sample size
= 34.1 million). The number of prescriptions for prostaglandin
analogs increased over the 4 year period (1.7 million in 1999 to
2.2 million in 2003). The number of prescriptions for beta-block-
ers decreased by approximately 47% from 1999 to 2003 (1.9
million to 1 million). Compared to beta-blockers, the odds of
patients receiving a prescription of prostaglandin analogs in year
2003 were twice as much as in year 1999 (95% CI: 1.29–4.48).
Patients’ sociodemographic characteristics such as age, gender,
race, source of payment, and physicians’ specialty were not sig-
niﬁcantly associated with the prescribing patterns these medica-
tions. CONCLUSION: In the nationally representative sample
of glaucoma patients, there was an increasing trend in the
number of prescriptions for prostaglandins. Superior clinical
effects, improved therapeutic index, safety, efﬁcacy, and ease of
administration with prostaglandin analogs such as latanoprost
may be contributing to the higher number of prescriptions.
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OBJECTIVES: Glaucoma is an ocular disease resulting in irre-
versible loss of visual function. Early identiﬁcation and treatment
has been demonstrated to improve outcomes, but incurs addi-
tional costs. This analysis was performed to determine the incre-
mental cost-effectiveness of early compared to late treatment 
of patients with Primary Open Angle Glaucoma (POAG).
METHODS: A decision analytic Markov model was developed
using a 25-year time horizon. The perspective was that of the
Ministry of Health and Long-term Care of Ontario, Canada;
thus, included only direct medical costs. Health states were
deﬁned according to mean visual ﬁeld deviation scores as mild
(0 to -4.9), moderate (-5.0 to -11.9), severe (-12 to -19.9), and
legally blind (-20+). The primary outcome was deﬁned as vision
years gained (VYG), i.e., time prior to reaching the legally blind
(absorbing) state. Costs and outcomes were derived from the lit-
erature; expert opinion was consulted where necessary. All costs
are reported in 2005 Canadian dollars. All costs and outcomes
were discounted at a 5% rate. The pharmacoeconomic outcome
was incremental cost per VYG. Various one-way and multi-vari-
able probabilistic sensitivity analyses were performed to test the
robustness of the results. RESULTS: Total discounted costs 
of early and late treatment were $7107 and $5608, respectively.
Differences in costs were attributed to an increased need for
resource intensive procedures and physician visits, approxi-
mately 75% of the total cost of the severe and legally blind health
states. Total expected VYG were 13.07 for early treatment and
12.65 for late treatment. The incremental cost effectiveness ratio
was $3,543/VYG. Results were sensitive to decreases in the rate
of disease progression and time horizon and increases in 
the yearly cost of treating patients with mild disease. 
CONCLUSIONS: Early treatment of patients diagnosed with
POAG is a reasonably cost-effective choice, providing added
years of vision.
